Car T-Cell
Entity.
- Evidence
- 33 documents · 18 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 3 Sept 2026, last seen 14 Oct 2026
- Measured
- 3% of mentions say something specific about it; the rest only name it
- As of
- 15 Oct 2026
Where this comes from
- The ASCO Post · 2026-10-09 · How Does CAR T-Cell Therapy Factor in With Tafasitamab in DLBCL (opens the source in a new tab)
- The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy (opens the source in a new tab)
- European Medical Journal · 2026-09-24 · Fatal Inflammatory Risks Associated with CAR T-Cell Therapy (opens the source in a new tab)
What is claimed about it
- Single source: Reported by one source so far.
- Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 1) Single source · first reported 10 Oct 2026